Generic placeholder image

Recent Patents on Inflammation & Allergy Drug Discovery


ISSN (Print): 1872-213X
ISSN (Online): 2212-2710

The Usefulness of the Multiple Allergen Simultaneous Test-Chemiluminescent as Compared to the Phadia Immunocap IgE Test Panel System in Children and Adolescents

Author(s): Ole D. Wolthers and Morten Staberg

Volume 7, Issue 1, 2013

Page: [96 - 99] Pages: 4

DOI: 10.2174/1872213X11307010096

Price: $65


Several patents of methods for diagnostic work-up of IgE-mediated disease have recently been acclaimed. The aim of the present study was to assess the diagnostic usefulness of the Multiple allergen simultaneous testchemiluminescent assay® (MAST CLA) as compared to the Phadia Immunocap® (Phadia CAP) allergen-specific IgE test panel system. The design was a prospective, observational study in which MAST CLA and Phadia CAP test panels were assessed in 105 children aged 1 to 17 years (46 girls and 59 boys) with a suspected diagnosis of rhinoconjunctivitis, asthma, eczema or food allergy. The MAST CLA screening panel included 23 and 13, the Phadia CAP 10 inhalant and 6 food allergens. The MAST CLA screening panel found 353 sensitizations which were not detected by Phadia CAP, 93 (26.3%) of which were class 3 or 4 results. The sensitizations gave clinically useful information in 7 patients (6.6%). As compared to the Phadia CAP the MAST CLA screening test panel adds little to the diagnostic work-up of IgE mediated disease in children and adolescents.

Keywords: Allergy, allergic rhinitis, asthma, eczema, IgE, IgE tests, multiple allergen simultaneous test-chemiluminescent assay, Phadia CAP test, IgE panel screening tests, rhinoconjunctivitis

« Previous

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy